Replies to post #391 on SurModics Inc (SRDX)

[aslan2772]

" What I do not think we are likely to see is a standard of care that involves two different injected drugs taken in sequence."

What makes you think this?

"other AMD drug candidates have to aim high, hoping to supplant Lucentis/Avastin as a monotherapy in a substantial fraction of patients."

What better way to aim high than to put your drug on a durable implant?